Triazolopyridazine LRRK2 kinase inhibitors

被引：24

作者：

Franzini, Maurizio ^{[1
]}

Ye, Xiaocong M. ^{[1
]}

Adler, Marc ^{[2
]}

Aubele, Danielle L. ^{[1
]}

Garofalo, Albert W. ^{[1
]}

Gauby, Shawn ^{[3
]}

Goldbach, Erich ^{[3
]}

Probst, Gary D. ^{[1
]}

Quinn, Kevin P. ^{[3
]}

Santiago, Pam ^{[3
]}

Sham, Hing L. ^{[1
]}

Tam, Danny ^{[4
]}

Anh Truong ^{[1
]}

Ren, Zhao ^{[4
]}

机构：

[1] Elan Pharmaceut, Dept Med Chem, San Francisco, CA 94080 USA

[2] Elan Pharmaceut, Dept Mol Design, San Francisco, CA 94080 USA

[3] Elan Pharmaceut, Dept Drug Metab & Pharmacokinet, San Francisco, CA 94080 USA

[4] Elan Pharmaceut, Dept Assay Dev, San Francisco, CA 94080 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2013年 / 23卷 / 07期

关键词：

LRRK2; Parkinson's; Inhibition; Kinase; Treatment; Discovery; Wild-type; G2019S mutant; Phosphorylation; SAR; Activity; Selectivity; Bioisostere; Hinge; HTS; Oxidative metabolism; Binding mode; Synthesis; CENTER-DOT-LICL; PARKINSONS-DISEASE; HETEROAROMATICS; AROMATICS; ZINCATION; TARGETS; BINDING;

D O I：

10.1016/j.bmcl.2013.02.043

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Leucine-rich repeat kinase 2 (LRRK2) has been implicated in the pathogenesis of Parkinson's disease (PD). Inhibition of LRRK2 kinase activity is a therapeutic approach that may lead to new treatments for PD. Herein we report the discovery of a series of [1,2,4]triazolo[4,3-b]pyridazines that are potent against both wild-type and mutant LRRK2 kinase activity in biochemical assays and show an unprecedented selectivity towards the G2019S mutant. A structural rational for the observed selectivity is proposed. (C) 2013 Elsevier Ltd. All rights reserved.

引用

下载

页码：1967 / 1973

页数：7

共 50 条

[1] Development of LRRK2 Kinase Inhibitors for Parkinson's Disease
Galatsis, Paul
Henderson, Jaclyn
Kormos, Bethany L.
Hirst, Warren D.
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 49, 2014, 49 : 43 - 58
[2] Unlocking the secrets of LRRK2 function with selective kinase inhibitors
Dzamko, Nicolas
Halliday, Glenda M.
FUTURE NEUROLOGY, 2013, 8 (03) : 347 - 357
[3] Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease
West, Andrew B.
EXPERIMENTAL NEUROLOGY, 2017, 298 : 236 - 245
[4] LRRK2 Kinase Activity Is Dependent on LRRK2 GTP Binding Capacity but Independent of LRRK2 GTP Binding
Taymans, Jean-Marc
Vancraenenbroeck, Renee
Ollikainen, Petri
Beilina, Alexandra
Lobbestael, Evy
De Maeyer, Marc
Baekelandt, Veerle
Cookson, Mark R.
PLOS ONE, 2011, 6 (08):
[5] Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond
Goering, Stefan
Taymans, Jean-Marc
Baekelandt, Veerle
Schmidt, Boris
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (19) : 4630 - 4637
[6] Novel cinnoline-based inhibitors of LRRK2 kinase activity
Garofalo, Albert W.
Adler, Marc
Aubele, Danielle L.
Bowers, Simeon
Franzini, Maurizio
Goldbach, Erich
Lorentzen, Colin
Neitz, R. Jeffrey
Probst, Gary D.
Quinn, Kevin P.
Santiago, Pam
Sham, Hing L.
Tam, Danny
Truong, Anh P.
Ye, Xiaocong M.
Ren, Zhao
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (01) : 71 - 74
[7] Inhibition of LRRK2 or Casein Kinase 1 Results in LRRK2 Protein Destabilization
T. De Wit
V. Baekelandt
E. Lobbestael
Molecular Neurobiology, 2019, 56 : 5273 - 5286
[8] Inhibition of LRRK2 or Casein Kinase 1 Results in LRRK2 Protein Destabilization
De Wit, T.
Baekelandt, V.
Lobbestael, E.
MOLECULAR NEUROBIOLOGY, 2019, 56 (08) : 5273 - 5286
[9] Structural Characterization of LRRK2 Inhibitors
Gilsbach, Bernd K.
Messias, Ana C.
Ito, Genta
Sattler, Michael
Alessi, Dario R.
Wittinghofer, Alfred
Kortholt, Arjan
JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (09) : 3751 - 3756
[10] Characterization of LRRK2 kinase activity
Ryder, J. W.
Anderson, B. D.
Huss, K. A.
Wang, X.
Qian, Y. -W.
Campbell, R. M.
Merchant, K. M.
MOVEMENT DISORDERS, 2008, 23 (01) : S29 - S30

← 1 2 3 4 5 →